Indo-Bangla Pharmaceuticals Limited

IBP

BD0494IBPL08

Pharmaceuticals

End-of-day quote Dhaka S.E. Other stock markets 03:30:00 30/06/2024 am IST			5-day change	1st Jan Change
13.3 ^BDT	-2.21%		-1.48%	-29.63%

13/05	Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
11/02	Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI

Indo-Bangla Pharmaceuticals Limited Recommends No Dividend for the Year Ended June 30, 2023

October 29, 2023 at 08:35 pm IST

The Board of Directors of Indo-Bangla Pharmaceuticals Limited has recommended No Dividend for the year ended June 30, 2023.

Latest news about Indo-Bangla Pharmaceuticals Limited

Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	13/05	CI
Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	11/02	CI
Indo-Bangla Pharmaceuticals Limited Recommends No Dividend for the Year Ended June 30, 2023	29/23/29	CI
Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2023	15/23/15	CI
Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	28/23/28	CI
Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	28/23/28	CI
Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	13/23/13	CI
Indo-Bangla Pharmaceuticals Limited Announces Purchase of Land	05/22/05	CI
Indo-Bangla Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended on June 30, 2021	31/21/31	CI
Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2020	12/20/12	CI
47,669,000 Ordinary Shares of Indo-Bangla Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 1-OCT-2020.	01/20/01	CI
Indo-Bangla Pharmaceuticals Limited Announces Address Change of Corporate Office	17/19/17	CI
Indo-Bangla Pharmaceuticals Limited Announces Manufacturing Agreement with Rhk Global (Hk) Ltd	27/19/27	CI
Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the Third Quarter Ended March 31, 2019	05/19/05	CI
Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the Second Quarter Ended December 31, 2018	31/19/31	CI
Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the Year Ended June 30, 2018	28/18/28	CI
Indo-Bangla Pharmaceuticals Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended on September 30, 2018	18/18/18	CI
25,331,000 Ordinary Shares of Indo-Bangla Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 1-OCT-2018.	01/18/01	CI
Indo-Bangla Pharmaceuticals Limited has completed an IPO in the amount of BDT 200 million.	11/18/11	CI
Indo-Bangla Pharmaceuticals Limited has filed an IPO in the amount of BDT 200 million.	02/17/02	CI

Chart Indo-Bangla Pharmaceuticals Limited

Duration

Period

Chart Indo-Bangla Pharmaceuticals Limited

More charts

Indo-Bangla Pharmaceuticals Limited is a Bangladesh-based pharmaceutical company. The Company is engaged in manufacturing and selling all kinds of medicines, medical preparations, drugs & chemicals (Human Health). It manufactures more than 450 generic drugs for 5,300 registered brands. It produces more than 90 brands. The Companyâs pharma portfolio encompasses various categories, including analgesics, respiratory, cardiovascular, central nervous system, dermatology, and gastrointestinal. Its products include Tablet I-Pedom 10mg, Tablet Indophylline 100mg, Tablet sulbumol plus 4.0mg, Tablet Sulbumol 2.0mg, Tablet Albendox 400mg, Tablet Mebendox 100mg, Tablet I-Fol Plus, Tablet I-Fol, Tablet Indosin, Tablet Indo-Fila 100mg, Tablet Indomol Plus, Tablet Trialugel and Tablet ICet 10mg.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
INDO-BANGLA PHARMACEUTICALS LIMITED	-29.63%	13.14M
ELI LILLY AND COMPANY	+54.14%	823B
NOVO NORDISK A/S	+42.31%	641B
JOHNSON & JOHNSON	-6.59%	352B
MERCK & CO., INC.	+16.90%	324B
ABBVIE INC.	+8.09%	301B
ASTRAZENECA PLC	+14.00%	241B
ROCHE HOLDING AG	+1.64%	223B
NOVARTIS AG	+13.66%	218B
AMGEN INC.	+7.71%	167B